Terug naar bedrijfspagina

Nieuws over Oxurion (ThromboGenics)

25/07/2024 Oxurion - Samenvoeging van Aandelen (25.07.2024)

11/07/2024 Oxurion - verduidelijkt de agenda van de buitengewone algemene vergadering die op 24 juli 2024 zal worden gehouden (11.07.2024)

08/07/2024 Oxurion - tekent een intentieverklaring en gaat exclusieve onderhandelingen aan om mogelijk een toonaangevende Franse CRO in stamcelproductie over te nemen (08.07.2024)

04/07/2024 Oxurion - kondigt resultaten aan van de Buitengewone Algemene Vergadering (BAV) van 4 juli 2024 en roept een nieuwe BAV bijeen op 24 juli 2024. (04.07.2024)

04/06/2024 Oxurion - Announces Extraordinary General Shareholders’ Meeting (04.06.2024)

27/05/2024 Oxurion - Receives Transparency Notification from Atlas Special Opportunities LLC (27.05.2024)

23/05/2024 Oxurion Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie (23.05.2024)

23/05/2024 Oxurion - Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 (23.05.2024)

16/05/2024 Oxurion - ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC (16.05.2024)

14/05/2024 Oxurion - Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (14.05.2024)

13/05/2024 Oxurion - Receives Transparency Notification from Atlas Special Opportunities LLC (13.05.2024)

06/05/2024 Oxurion - Belangrijke vooruitgang in het O&O programma van Oxurion op het gebied van Geografische Atrofie secundair aan AMD (06.05.2024)

25/04/2024 Oxurion - Receives Transparency Notification from Atlas Special Opportunities LLC (25.04.2024)

15/04/2024 OXURION - Publicatie jaarverslag – Jaarlijkse Aandeelhoudersvergadering (15.04.2024)

11/04/2024 Oxurion - Receives EUR 450,000 in the framework of the Atlas Funding Program Eleventh tranche fully issued and paid-up (11.04.2024)

11/04/2024 Oxurion - ontvangt transparantiekennisgevingen van Atlas Special Opportunities LLC (11.04.2024)

08/03/2024 Oxurion - ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC (08.03.2024)

06/03/2024 Oxurion - Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up (06.03.2024)

14/02/2024 Oxurion - Receives EUR 850,000 in the framework of the Atlas Funding Program (14.02.2024)

05/02/2024 Oxurion - focus op de nieuwe strategische en financiële plannen (05.02.2024)

25/07/2023 Oxurion - Receives Upfront Payment of $400,000 Following Oncurious Asset License by VIB (25.07.2023)

12/06/2023 Oxurion - Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema (12.06.2023)

26/05/2023 Oxurion - Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema (26.05.2023)

23/05/2023 Oxurion - Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLC (23.05.2023)

08/05/2023 OXURION - Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op ATLAS Conversie-Notificatie (08.05.2023)

28/04/2023 Oxurion - Issues EUR 2.0 million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLC (27.04.2023)

03/04/2023 Oxurion - publiceert jaarverslag 2022 (03.04.2023)

22/03/2023 Oxurion - Issues EUR 2.8 million in Bonds of Funding Program with Atlas Special Opportunities LLC (21.03.23)

15/03/2023 Oxurion - Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes (15.03.2023)

02/03/2023 OXURION - Funding Program between Oxurion and Negma Ends - Announces Subscription Agreement with Atlas Providing the Company with Up To €20 Million in Funding (02.03.2023)

27/01/2023 Oxurion - Provides Further Details Concerning the Second Amendment to Negma Funding Program (27.01.2023)

25/01/2023 Oxurion - Announces Second Amendment to Negma Funding Program (25.01.2023)

15/12/2022 Oxurion - Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macular Edema Following Interim Analysis Trial Continues with Top-line Data Anticipated 2H 2023 (15.12.2022)

23/11/2022 Oxurion - Further Improves THR-149 Patent Position (23.11.2022)

07/09/2022 Oxurion - Publishes First Half 2022 Results (07.09.2022)

05/09/2022 Oxurion - Announces Amendment to Funding Program with Negma Group for EUR 6 Million in Funding (05.09.2022)

31/05/2022 OXURION - Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA (31.05.2022)

25/05/2022 Oxurion - Announces Upcoming Preclinical Presentation on THR-149 at KININ2022 (25.05.2022)

09/05/2022 Oxurion - Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME) (09.05.2022)

30/03/2022 Oxurion NV - enters into a Capital Commitment of up to €30 Million with Negma Group (30.03.2022)

28/03/2022 Oxurion - jaarverslag 2021 (28.03.2022)

22/02/2022 Oxurion NV - announces 2021 Full Year Results and 2022 Outlook - Voting Rights (22.02.2022)

14/02/2022 Oxurion - kondigt nieuwe gegevens aan over THR-149 Fase 2 klinische studie (“KALAHARI”) in DME op de Angiogenesis, Exudation, and Degeneration 2022 Conference (14.02.2022)

07/01/2022 Oxurion - geeft update over voortgang klinische pijplijn (07.01.2022)

11/10/2021 OXURION - Positieve fase 2 Deel A THR-149-gegevens gedeeld op de jaarlijkse wetenschappelijke bijeenkomst van de America Society of Retinal Specialists (ASRS) (11.10.2021)

17/08/2021 Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal (17.08.2021)

10/06/2021 OXURION - bevestigt goedkeuring en indiening van de onderzoeksaanvraag voor nieuwe geneesmiddelen bij de FDA om fase 2-onderzoek te starten ter evaluatie van THR-687 voor diabetisch macula-oedeem (DME) (10.06.2021)

08/06/2021 OXURION - Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME) (08.06.2021)

30/04/2021 OXURION NV - Presenting Scientific Data at ARVO 2021 Annual Meeting (30.04.2021)

12/04/2021 Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in Paediatric Subjects with Relapsed or Refractory Medulloblastoma Presented at the American Association for Cancer Research 2021 Annual Meeting (12.04.2021)

06/04/2021 Oxurion NV - enters into a Capital Commitment of up to €30 Million with Negma Group (06.04.2021)

18/03/2021 Oxurion NV - Business and Financial Update – FY 2020 (18.03.2021)

15/10/2020 Oxurion - Business Update – Q3 2020 (15.10.2020)

18/09/2020 Oxurion - Business Update - H1 2020 (17.9.2020)

01/09/2020 Oxurion - Reports First Patient Dosed in Phase 2 study evaluating THR-149 f (1.9.2020)

03/08/2020 Oxurion - appoints Grace Chang, M.D., Ph.D. as Chief Medical Officer (3.8.2020)

03/08/2020 Oxurion NV - appoints Grace Chang as Chief Medical Officer (3.8.2020)

07/05/2020 Oxurion NV Business Update - Q1 2020 (7.5.2020)

13/03/2020 Oxurion NV Business Update – FY 2019 (13.3.2020)

07/01/2020 Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME

18/10/2019 Oxurion - Business Update Q3 (18.10.2019)

09/10/2019 Oxurion-Poster Presentation Featuring Positive Topline data from Phase 1 Trial(9.10.2019)

05/09/2019 Oxurion NV Business Update – H1 2019 (5.9.2019)

02/09/2019 Oxurion - late-breaker presentation of topline THR-149 Phase 1 clinical data at EURETINA (2.9.2019)

21/08/2019 Oxurion wordt voetje gelicht door testdata (KBC)

20/08/2019 Oxurion - Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 (anti-PLGF), in Combination with Ranibizumab, for DME (20.8.2019)

06/06/2019 Oxurion NV - Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting (6.6.2019)

08/05/2019 Oxurion NV - business update Q1 2019 (8.5.2019)

24/04/2019 Oxurion NV - full enrollment Phase 1 trial THR149 (24.04.2019)

04/04/2019 Oxurion-full enrollment Phase 2 of the combination of anti-PlGF (THR-317) and anti-VEGF (ranibizumab) for treatment of DME (4.4.2019)

07/03/2019 Oxurion NV Business Update – FY 2018 (7/03/19)

06/02/2019 Oxurion (LifeSci)